Extended Data Fig. 7: Additional characterization of ABT-199 and JQ-1-resistant AML cells.
a, 8-point dose-response curves of ABT-199 in parental and ABT-199-resistant OCI-AML2 cells. b, Immunoblot analysis of EZH2 and MYC in parental and ABT-199-resistant OCI-AML2 cells. c, Fold-change of MYC transcripts across matched parental and JQ-1-resistant AML cell lines. d, Immunoblot analysis of NSD2 and NSD3 across matched parental and JQ-1 resistant AML cell lines. e,f, ARV771 GI50 values of parental and JQ-1-resistant OCI-AML2 (e) and MOLM-13 (f). g, Immunoblot analysis of phosphorylated EZH2 at T487 and S21 in parental and JQ-1 resistant OCI-AML2 cells. h, Immunoblot analysis of ubiquitin and EZH2 following immunoprecipitation of EZH2 in OCI-AML2 cells. i, Immunoblot analysis of EZH2 following treatment of JQ-1 resistant OCI-AML2 cells with CDK1 inhibitor (CDK1i) or proteasome inhibitor (Bortezomib) for 24 hours. a,c,e,f; Data are mean ± SEM for n = 3 biologically independent experiments. c,e,f; P-values computed by two-sided two-sample t-Test for equal means. b,d,g–i; Representative immunoblots of n = 3 independent experiments. Uncropped blots in Source Data.
